Scarica l'app Stockscreener
3.08
5.81%
-0.19
Dopo l'orario di chiusura:
3.05
-0.03
-0.97%
Precedente Chiudi:
$3.27
Aprire:
$3.3
Volume 24 ore:
115.10K
Relative Volume:
0.26
Capitalizzazione di mercato:
$2.23M
Reddito:
$4.96M
Utile/perdita netta:
$-6.82M
Rapporto P/E:
-0.0471
EPS:
-65.4
Flusso di cassa netto:
$-6.64M
1 W Prestazione:
-27.01%
1M Prestazione:
-35.02%
6M Prestazione:
-12.40%
1 anno Prestazione:
-57.21%
Intervallo 1D:
$2.86
$3.30
Intervallo di 1 settimana:
$2.86
$4.29
Portata 52W:
$2.414
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Nome
Inmed Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 669-7207
Indirizzo
1445-885 WEST GEORGIA ST., VANCOUVER
Confronta INM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
3.08 | 2.23M | 4.96M | -6.82M | -6.64M | -65.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - MSN
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Yahoo Finance
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus.com
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
InMed Pharmaceuticals Secures $10M Equity Purchase Agreement in Strategic Financing Move - StockTitan
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% – Time to Sell? - Defense World
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.86 (As of Dec. 05, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.90 (As of Dec. 03, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Shares Outstanding (EOP) : 0.67 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Total Liabilities : $2.07 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Debt-to-Equity : 0.13 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) EBITDA : $-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Cash, Cash Equivalents, Marketa - GuruFocus.com
INM (InMed Pharmaceuticals) Growth Rank : 0 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Machinery, Furniture, Equipment : $0.04 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com
INM (InMed Pharmaceuticals) Total Inventories : $1.22 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Net Income : $-6.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Inventory Turnover : 0.63 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Revenue per Share : $49.03 (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 9-Day RSI : 44.83 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 26, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Ending Cash Position : €5.03 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Book Value per Share : €11.34 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Accounts Receivable : €0.26 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Pre-Tax Income : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Days Inventory : 147.82 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) GF Score : 43/100 (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings per Share (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Median PS Value : €0.00 (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Asset Turnover : 0.11 (As of Sep. 2024) - GuruFocus.com
Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):